Regeneration Technologies loses half its value as it delays results
This article was originally published in Clinica
Executive Summary
Regeneration Technologies' (RTI) shares lost more than half their value last week, reaching $4.96 before trading in the company was stopped. The drop came after the company announced that it was delaying the release of its fourth-quarter and full-year results until it finishes evaluating "certain inventory issues". Regeneration's current share price marks a new year-low and compares with a 52-week high of over $15.